Since it is known that a high bone marrow MVD is associated with a poor prognosis and that the reduction of microvessels correlates with treatment response [24, 25], we hypothesize that this particular patient subgroup, i.e., AML-MRC, might profit from the antiangiogenic effects of lenalidomide. Here, CD200 is linked to acute myeloid leukemia.